MDMA
3,4-methylenedioxymethamphetamine
3-5 hours
30-60 minutes
empathogen
First synthesized by Merck chemists in 1912 as a byproduct o…
- ⚡Profound empathy and emotional openness — reduced fear and defensiveness
- ⚡Euphoria and deep sense of well-being
- ⚡Increased energy and sociability
- ⚡Tactile enhancement and heightened physical pleasure
- ⚡Reduced fear, anxiety, and emotional defensiveness
- ⚡Heightened sensory experience
- ⚡Increased capacity for introspection and processing difficult emotions
- ⚠️Hyperthermia (overheating) is the primary acute risk — especially dangerous in hot, crowded environments with dancing
- ⚠️Both dehydration AND overhydration are dangerous — drink approximately 500ml/hour if active, less if not
- ⚠️Neurotoxicity risk with repeated heavy use — minimum 3-month gaps strongly recommended
- ⚠️Dangerous interactions with SSRIs, MAOIs, and stimulants — risk of fatal serotonin syndrome
- ⚠️Cardiovascular strain — avoid with any heart conditions
- ⚠️Post-experience low mood ('Tuesday blues') common for 1-3 days — plan for recovery time
No traditional use — entirely modern. Underground therapists used it extensively in the late 1970s and early 1980s for couples therapy, trauma work, and addiction treatment before it was made Schedule I in 1985. The therapy pioneer Ann Shulgin described sessions as producing 'three years of therapy in one afternoon.'
Phase 3 clinical trials by MAPS for PTSD. FDA Breakthrough Therapy designation. Approved in Australia (2023). FDA advisory committee voted against approval in 2024 due to trial design concerns — additional Phase 3 trial in progress.
Schedule I in the US and most countries. Approved for PTSD therapy in Australia since February 2023 — the first country to approve a psychedelic as medicine. Phase 3 clinical trials ongoing in the US, Canada, Israel, and Europe.